110 results about "Proto-Oncogenes" patented technology

The present invention relates to the use of proteins which are differentially expressed in primary brain tumor tissues, as compared to normal brain tissues, as biomolecular targets for brain tumor treatment therapies. Specifically, the present invention relates to the use of immunotherapeutic and immunoimaging agents which specifically bind to one or more of human proteins angiopoietin related protein 2 (ARP-2,) secreted protein acidic, rich in cysteine (SPARC,) c-met proto-oncogene (C-MET,) brevican (BEHAB,) CD-44 antigen (CD-44,) tetraspanin 3 (TSPN3,) pleiotrophin (PTN,) osteopontin (OPN,) vasoactive intestinal peptide receptor-2 (VIPR-2,) and receptor protein tyrosine phosphatase zeta (PTPζ) for the treatment and visualization of brain tumors in patients. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the methods of the invention. The present invention also provides novel splice variants of protein PTPζ, PTPζ SM1 and PTPζ SM2. Nucleic acid probes specific for the spliced mRNA encoding these variants and affinity reagents specific for the novel proteins are also provided.

The invention belongs to the medicine and chemical industry field, which discloses a quinnazolidone derivative, a preparation method thereof and a purpose of serving as anticarcinogen. The structural formula of the quinnazolidone derivative is that: R1 is F, CL, Br or I, R2 is NH (CH2) nNR4, NR4 or NH(CH2)n-Ar, R3 is NHCO (CH2) nNR4 or CONH (CH2) nNR4, and m equals to 1,2 or 3. -Ar represents various aromatic nucleus, including various heteroaromatic compounds; n equals to 1, 2, 3, 4 or 5; R4 represents C1-6alkyl, C3-6 naphthenic base, piperidyl, morpholinyl, piperazine, or quinoxaline and the like or R1 equals to H, R2 equals to R3 equals to NHCO (CH2) nNR4 or R2 equals to H, R1 equals to R3 equals to NHCO (CH2) nNR4, and m equals to 2 or 3. The invention discloses the preparation method of the quinnazolidone derivative and the purpose of serving as the anticarcinogen at the same time. The quinnazolidone derivative has the advantages of strong inhibitory action on the expression of telomere DNA, c-myc and other proto-oncogenes DNA, obvious inhibitory action on various cancer cell strains, little toxicity on normal cells and wide application space on preparing the anticarcinogen.

The invention relates to application of an inhibitor of GINS2 genes or protein to the preparation of antitumor drugs. A small-molecular interference RNA sequence aiming at the human GINS2 genes, an RNA interference vector and an RNA interference lentivirus are designed, the silencing efficiency of the GINS2 genes and influence of the GINS2-siRNA lentivirus on the proliferation capacity and apoptosis level of tumor cells are further detected, results show that the proliferation and growth of the tumor cells can be inhibited effectively and the apoptosis of the tumor cells can be promoted after an RNAi method is used to lower the expression of the GINS2 genes, the results indicate that the GINS2 genes are proto-oncogenes and can be used as the targets of tumor treatment, and the RNAi method for silencing the expression of the GINS2 can be used as an effective method to inhibit tumor development. The built siRNA, the RNA interference vector and the RNA interference lentivirus can be used for preparing efficient antitumor drugs.

The invention discloses a compound for selectively degrading a CDK subtype in a targeted manner, and belongs to the field of biomedicine. The compound is a compound shown as a formula I or a stereoisomer, a geometrical isomer, a tautomer, a nitrogen oxide compound, a hydrate, a solvent compound, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and can selectively degrade CDK2or CDK2 / 9 so as to block the synthesis process of DNA and achieve the proliferation of cancer cells, wherein certain compounds capable of selectively degrading CDK subtypes in the targeted manner canalso down-regulate signal channels including proto-oncogene products c-MYC and MCL-1, can strongly inhibit the proliferation of cancer cells, and have a potential treatment effect. X-Y-Z Formula I isperformed, wherein: X represents a cyclin kinase inhibitor, Z represents a CRBN ligand, Y represents a chain linking X and Z, and X is a structure as shown in a formula II or a formula III.

The invention discloses a genetic therapy breast cancer drug preparation method based on microfluidic chip, which includes that: the method adopts biological molecules as computation medium to compute the cancer-related gene expression through biochemical reaction; when the result meets the requirement, the anti-cancer drug is automatically synthesized and released in targeted manner; the anti-cancer drug is complete suicide gene; the biological molecules used as computation medium are DNA molecules and / or enzyme; the oncogene related to breast cancer includes: C-erbB-2, EGFR, c-myc, ras, int-2, bcl-2, BAG-1, BCSG-2 and survivin; the cancer suppressor gene related to breast cancer includes P53, nm23, PTEN, Rb, P16, P21, CHEK2, BRCA1 and BRCA2. The invention can synthesize and release anti-cancer drugs for breast cancer on specified conditions; and the anti-cancer drugs are complete suicide gene. The method can be combined with the nanometer technology and micromachining technology to help improve the treatment effect.

A method of producing nanovesicles comprising an oligonucleotide inhibitor to an oncogene or a proto-oncogene or the gene product thereof, said method comprises a) introducing a DNA sequence encoding an oligonucleotide capable of inhibiting a human oncogenic or proto-oncogenic transcription factor, into a mammalian cell; b) allowing the cell to express said inhibitor oligonucleotide; and c) obtaining nanovesicles containing said inhibitor oligonucleotide from said cell. Nanovesicles produced by the claimed method can be effectively and specifically targeted to e.g. cancer cells to deliver the inhibitor oligonucleotide.

The invention discloses a medication selection and curative effect detection reagent kit of glivec assistance treatment of a gastrointestinal stromal tumor, and relates to a detection reagent kit for molecular biology and medicine. The kit comprises BCR-ABL (Abelson proto-oncogene-breakpoint cluster region) gene PCR (polymerase chain reaction) liquid, Taq (thermus aquaticus) enzyme, a control, a matched multiplex PCR amplification procedure and a wrappage. The kit helps to select appropriate drugs for the gastrointestinal stromal tumor and evaluates a curative effect of the individual glivec assistance treatment of the gastrointestinal stromal tumor by detecting whether a glivec drug target site BCR-ALB fusion gene exists, and is applicable to multiple fields of selection of clinical assistance medication, prognosis judgment and the like of the gastrointestinal stromal tumor.

The invention discloses a construction method and an application of a primary MM (multiple myeloma) mouse model. The method comprises steps as follows: high-frequency mutated proto-oncogenes are screened from sequencing results of MM patient samples and taken as driver genes, and a retroviral vector is constructed, infects IgM positive B cells of a mouse in vitro and performs induced transformation into an MM model in the body of the mouse; proto-oncogene combinations of ten patients are screened out, and cMYC and KRAS12V are determined to be the best. The model is applied to research of humanMM pathogenesis, chemical drug screening of MM, improvement of existing therapeutic schedules, evaluation of new drug or targeted drug combination and evaluation of the model for cellular immunotherapy and antibody therapy. The constructed primary MM model has great significance for scientific research of molecular mechanism of MM genesis and development and exploration of new MM treatment targets. The animal module is fast to form and realizes 100% tumor formation, and a theoretical basis and an evaluation system are provided for development of new target identification and new treatment method evaluation of MM on the basis of biotherapy.

The invention belongs to the fields of medicament and chemical industry, and discloses a carbazole derivative, a preparation method of the carbazole derivative, and an application of the carbazole derivative serving as an anticancer drug. The structural formula of the carbazole derivative is shown in the specification, wherein R1 is piperidyl, morpholinyl, piperazinyl or Bielin group; n is 1, 2 or 3; and R2 is pyrazolyl or pyridyl. At the same time, the invention discloses a preparation method of the carbazole derivative and an application of the carbazole derivative serving as the anticancer drug. The carbazole derivative has strong inhibiting action on the expression of telomere DNA (deoxyribonucleic acid) and DNA of c-myc and other proto-oncogene, has significant inhibiting action on multiple cancer cell strains, has low toxicity to normal cells, and has broad application space in preparation of anticancer drugs.